• ATS-9R: Precision Gene Silencing in Adipocytes Explained

  2026-05-22

  ATS-9R (Adipocyte-targeting sequence-9-arginine) is a transformative tool for targeted gene silencing in white adipose tissue, enabling researchers to model and potentially treat obesity-linked inflammation with high efficiency and minimal toxicity. Its Prohibitin-mediated uptake and nona-arginine-based nucleic acid condensation outperform traditional vectors, streamlining experimental workflows in metabolic research.

• ML216, BLM Helicase Inhibitor: Protocols for Synthetic Letha

  2026-05-21

  ML216 stands out as a selective BLM helicase inhibitor for dissecting DNA repair mechanisms and modeling synthetic lethality in cancer research. This article delivers data-backed workflows, troubleshooting strategies, and critical insights that empower researchers to maximize ML216’s impact in both cell-based and in vivo experimental designs.

• Anti-HMGB1 Rabbit Monoclonal Antibody: Technical Application

  2026-05-21

  The Anti-HMGB1 Rabbit Monoclonal Antibody (SKU MA3057) is designed for specific detection of HMGB1 protein in human, mouse, and rat samples across Western blot, immunohistochemistry, and flow cytometry assays. It addresses the need for stringent chromatin protein detection in research, but should not be applied in diagnostic or clinical workflows.

• Ademetionine in Neurological Disorders: Methylation Mechanis

  2026-05-20

  This review synthesizes clinical and biochemical evidence on S-adenosylmethionine (SAMe; ademetionine) as a central methyl donor in the nervous system, highlighting its role in methylation reactions and the treatment of neuropsychiatric disorders. Key findings reveal how SAMe modulates neurotransmitter metabolism and supports interventions for depression and dementia, emphasizing the translational potential of methyl donor therapies in CNS research.

• G418 Sulfate: Enhancing Genetic Selection and Antiviral Rese

  2026-05-20

  Geneticin (G-418 Sulfate) from APExBIO delivers precise, reproducible cell selection and robust antiviral workflow support. This article unpacks advanced experimental uses, protocol refinements, and troubleshooting strategies, empowering innovators in genetic engineering and virology alike.

• Refining In Vitro Drug Response Metrics for Cancer Research

  2026-05-19

  Schwartz's dissertation introduces a framework distinguishing between proliferative arrest and cell death in in vitro cancer drug assays, highlighting the importance of measuring these endpoints independently. These insights have significant implications for the evaluation and development of apoptosis-targeting agents, including advanced pan-Bcl-2 inhibitors.

• Forsythoside E: Advanced PKM2 Inhibition for Macrophage Meta

  2026-05-19

  Explore Forsythoside E as a next-generation PKM2 inhibitor for immunometabolic research. This article uniquely analyzes its mechanistic depth, translational relevance, and practical protocol parameters for macrophage polarization and sepsis-induced liver injury models.

• SLIT2 Suppresses EMT and Tumor Progression in Lung Adenocarc

  2026-05-18

  Chen et al. (2025) identify SLIT2 as a tumor suppressor in lung adenocarcinoma, demonstrating that its downregulation promotes tumor growth, migration, and epithelial-mesenchymal transition. Their integrative bioinformatics and experimental approach highlights SLIT2's potential as both a prognostic biomarker and therapeutic target, with implications for studying tumor microenvironment and immune cell infiltration.

• TG003 Cdc2-like Kinase Inhibitor: Precision Tools for Splici

  2026-05-18

  TG003 empowers researchers to dissect alternative splicing and model therapy resistance with unmatched selectivity for Clk kinases. Its nanomolar potency and translational relevance, especially in platinum-resistant cancer and exon-skipping studies, make it a cornerstone for experimental innovation.

• ATS-9R: Targeted Gene Silencing in Adipocytes for Metabolic

  2026-05-17

  ATS-9R (Adipocyte-targeting sequence-9-arginine) enables precise, non-viral gene delivery to white adipose tissue, revolutionizing obesity and insulin resistance research. Its prohibitin-mediated uptake and robust gene silencing outperform conventional vectors with minimal toxicity.

• ATS-9R: Redefining Adipose Tissue Gene Delivery for Inflamma

  2026-05-16

  Explore how ATS-9R (Adipocyte-targeting sequence-9-arginine) enables precise, non-viral gene silencing in adipocytes and adipose tissue macrophages, advancing research on obesity-associated inflammation and insulin resistance. This article delivers unique protocol insights and translational value beyond existing resources.

• CX-5461: RNA Polymerase I Inhibitor for Cancer Research

  2026-05-15

  CX-5461 is a potent, orally bioavailable RNA polymerase I inhibitor used in cancer research. It selectively impairs rRNA synthesis, induces cellular senescence and autophagy, and demonstrates robust activity against various solid tumor models. CX-5461 also enhances chemotherapeutic sensitivity in resistant cancer cells.

• E-4031: hERG Potassium Channel Blocker for 3D Cardiac Models

  2026-05-15

  E-4031 enables precise hERG potassium channel blockade, driving high-content cardiac electrophysiology research in both 2D and 3D settings. Here, we detail robust workflows and troubleshooting strategies uniquely tailored for organoid-compatible, spatiotemporally resolved pharmacological assays.

• p53/PUMA-Mediated Apoptosis via WRN Inhibition in MSI CRC

  2026-05-14

  This study demonstrates that inhibition or depletion of Werner (WRN) helicase triggers p53/PUMA-dependent apoptosis specifically in mismatch repair-deficient (MSI) colorectal cancer cells. The findings clarify the synthetic lethality mechanism involved and substantiate WRN as a rational therapeutic vulnerability in p53-wildtype MSI CRC.

• ML216: BLM Helicase Inhibition for Synthetic Lethality in On

  2026-05-14

  This thought-leadership article explores the strategic deployment of ML216, a potent BLM helicase inhibitor, within the context of synthetic lethality and mismatch repair-deficient (MSI) cancer research. Integrating mechanistic insights from seminal studies on RecQ helicase inhibition and p53/PUMA-mediated apoptosis, the discussion highlights the translational potential of ML216 as a precision DNA repair enzyme inhibitor. The article further distinguishes itself by providing actionable protocol parameters, competitive landscape analysis, and a forward-looking perspective for translational researchers.

15816 records 2/1055 page Previous Next 12345 下5页 Last page